ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2-Diagnostic Criteria and Appropriate Utilization.
暂无分享,去创建一个
Sanjiv J. Shah | R. Falk | V. Ferrari | R. Kwong | V. Murthy | J. Moon | C. Rapezzi | M. Maurer | S. Dorbala | A. Dispenzieri | E. Miller | G. Merlini | R. Slart | Y. Ando | A. Glaudemans | H. Verberne | O. Gheysens | M. Fontana | B. Hazenberg | S. Bokhari | J. Bourque | A. Kristen | J. Gillmore | M. Hanna | F. Ruberg | C. Quarta
[1] J. Moon,et al. Cardiac Structural and Functional Consequences of Amyloid Deposition by Cardiac Magnetic Resonance and Echocardiography and Their Prognostic Roles. , 2019, JACC. Cardiovascular imaging.
[2] D. Phelan,et al. Tenosynovial and Cardiac Amyloidosis in Patients Undergoing Carpal Tunnel Release. , 2018, Journal of the American College of Cardiology.
[3] J. Berk,et al. Once AL amyloidosis: not always AL amyloidosis , 2018, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[4] S. Rajkumar,et al. How I manage monoclonal gammopathy of undetermined significance. , 2018, Blood.
[5] M. Leon,et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement , 2017, European heart journal.
[6] M. Maurer,et al. Hip and knee arthroplasty are common among patients with transthyretin cardiac amyloidosis, occurring years before cardiac amyloid diagnosis: can we identify affected patients earlier? , 2017, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[7] P. Schoenhagen,et al. ACC/AATS/AHA/ASE/ASNC/HRS/SCAI/SCCT/SCMR/STS 2017 Appropriate Use Criteria for Multimodality Imaging in Valvular Heart Disease , 2017, Journal of Nuclear Cardiology.
[8] R. Falk,et al. AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy. , 2016, Journal of the American College of Cardiology.
[9] A. Dispenzieri,et al. Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. , 2016, Journal of the American College of Cardiology.
[10] James C Moon,et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis , 2016, Circulation.
[11] Harold Litt,et al. 2015 ACR/ACC/AHA/AATS/ACEP/ASNC/NASCI/SAEM/SCCT/SCMR/SCPC/SNMMI/STR/STS Appropriate Utilization of Cardiovascular Imaging in Emergency Department Patients With Chest Pain: A Joint Document of the American College of Radiology Appropriateness Criteria Committee and the American College of Cardiology , 2016, Journal of the American College of Cardiology.
[12] E. González-López,et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. , 2015, European heart journal.
[13] T. Sundt,et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.
[14] L. Shaw,et al. ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 multimodality appropriate use criteria for the detection and risk assessment of stable ischemic heart disease: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Heart Association, American Societ , 2014, Journal of the American College of Cardiology.
[15] Richard D. White,et al. 2013 ACCF/ACR/ASE/ASNC/SCCT/SCMR appropriate utilization of cardiovascular imaging in heart failure: a joint report of the American College of Radiology Appropriateness Criteria Committee and the American College of Cardiology Foundation Appropriate Use Criteria Task Force. , 2013, Journal of the American College of Cardiology.
[16] M. Dimopoulos,et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. , 2013, Blood.
[17] Manesh R. Patel,et al. Appropriate use of cardiovascular technology: 2013 ACCF appropriate use criteria methodology update: a report of the American College of Cardiology Foundation appropriate use criteria task force. , 2013, Journal of the American College of Cardiology.
[18] A. Flett,et al. Quantification of Myocardial Extracellular Volume Fraction in Systemic AL Amyloidosis: An Equilibrium Contrast Cardiovascular Magnetic Resonance Study , 2013, Circulation. Cardiovascular imaging.
[19] John Eng,et al. Normal Left Ventricular Myocardial Thickness for Middle-Aged and Older Subjects With Steady-State Free Precession Cardiac Magnetic Resonance: The Multi-Ethnic Study of Atherosclerosis , 2012, Circulation. Cardiovascular imaging.
[20] Warren J Manning,et al. ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 Appropriate Use Criteria for Echocardiography. A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, American Society of Nuclear Cardiology, , 2011, Journal of the American College of Cardiology.
[21] Manesh R. Patel,et al. ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. , 2010, Circulation.
[22] M. Keith,et al. American Academy of Orthopaedic Surgeons Clinical Practice Guideline on diagnosis of carpal tunnel syndrome. , 2009, The Journal of bone and joint surgery. American volume.
[23] Michael J Pentecost,et al. American College of Radiology white paper on radiation dose in medicine. , 2007, Journal of the American College of Radiology : JACR.
[24] G. Merlini,et al. Dangerous small B-cell clones. , 2006, Blood.
[25] R. Hendel,et al. ACCF proposed method for evaluating the appropriateness of cardiovascular imaging. , 2005, Journal of the American College of Cardiology.
[26] R. Falk,et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis , 2005, American journal of hematology.
[27] A. Balduini,et al. Serum N-Terminal Pro–Brain Natriuretic Peptide Is a Sensitive Marker of Myocardial Dysfunction in AL Amyloidosis , 2003, Circulation.
[28] L Goldman,et al. Expert panel vs decision-analysis recommendations for postdischarge coronary angiography after myocardial infarction. , 1999, JAMA.
[29] R H Brook,et al. A Method for the Detailed Assessment of the Appropriateness of Medical Technologies , 1986, International Journal of Technology Assessment in Health Care.
[30] Warren J Manning,et al. ACC/AATS/AHA/ASE/EACTS/HVS/SCA/SCAI/SCCT/SCMR/STS 2017 Appropriate Use Criteria for the Treatment of Patients With Severe Aortic Stenosis: A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, Americ , 2018, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[31] Biykem Bozkurt,et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.
[32] J. Berk,et al. Contemporary Reviews in Cardiovascular Medicine Transthyretin (TTR) Cardiac Amyloidosis , 2012 .
[33] A. P. Meijler,et al. Setting standards for effectiveness: a comparison of expert panels and decision analysis. , 1997, International journal for quality in health care : journal of the International Society for Quality in Health Care.